APA

Gerding D. N., Hecht D. W., Louie T., Nord C. E., Talbot G. H., Cornely O. A., Buitrago M., Best E., Sambol S., Osmolski J. R., Kracker H., Locher H. H., Charef P. & Wilcox M. (20161005). Susceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection. : The Journal of antimicrobial chemotherapy.

Chicago

Gerding D N, Hecht D W, Louie T, Nord C E, Talbot G H, Cornely O A, Buitrago M, Best E, Sambol S, Osmolski J R, Kracker H, Locher H H, Charef P and Wilcox M. 20161005. Susceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection. : The Journal of antimicrobial chemotherapy.

Harvard

Gerding D. N., Hecht D. W., Louie T., Nord C. E., Talbot G. H., Cornely O. A., Buitrago M., Best E., Sambol S., Osmolski J. R., Kracker H., Locher H. H., Charef P. and Wilcox M. (20161005). Susceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection. : The Journal of antimicrobial chemotherapy.

MLA

Gerding D N, Hecht D W, Louie T, Nord C E, Talbot G H, Cornely O A, Buitrago M, Best E, Sambol S, Osmolski J R, Kracker H, Locher H H, Charef P and Wilcox M. Susceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection. : The Journal of antimicrobial chemotherapy. 20161005.